当前位置: 首页 >> 检索结果
5965. Introducing High-Sensitivity Cardiac Troponin T as a Biomarker of OSA-Related Cardiovascular Morbidity in Obesity Hypoventilation Syndrome.
作者: Denis Monneret.;Philippe Giral.;Dominique Bonnefont-Rousselot.;Frederic Roche.
来源: Chest. 2016年150卷6期1408-1409页 5970. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
作者: Peter A Noseworthy.;Xiaoxi Yao.;Neena S Abraham.;Lindsey R Sangaralingham.;Robert D McBane.;Nilay D Shah.
来源: Chest. 2016年150卷6期1302-1312页
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians now have a choice between different NOACs, but there is no direct comparative effectiveness evidence to guide decision-making. We aimed to compare the effectiveness and safety of dabigatran, rivaroxaban, and apixaban in clinical practice.
5976. Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study.
作者: Susan R Kahn.;Andrew M Hirsch.;Arash Akaberi.;Paul Hernandez.;David R Anderson.;Philip S Wells.;Marc A Rodger.;Susan Solymoss.;Michael J Kovacs.;Lawrence Rudski.;Avi Shimony.;Carole Dennie.;Christopher Rush.;William H Geerts.;Shawn D Aaron.;John T Granton.
来源: Chest. 2017年151卷5期1058-1068页
We aimed to determine the frequency and predictors of exercise limitation after pulmonary embolism (PE) and to assess its association with health-related quality of life (HRQoL) and dyspnea.
5977. ICU Telemedicine Program Financial Outcomes.
作者: Craig M Lilly.;Christine Motzkus.;Teresa Rincon.;Shawn E Cody.;Karen Landry.;Richard S Irwin.; .
来源: Chest. 2017年151卷2期286-297页
ICU telemedicine improves access to high-quality critical care, has substantial costs, and can change financial outcomes. Detailed information about financial outcomes and their trends over time following ICU telemedicine implementation and after the addition of logistic center function has not been published to our knowledge.
5979. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
作者: Fernando J Martinez.;Klaus F Rabe.;Gary T Ferguson.;Leonardo M Fabbri.;Stephen Rennard.;Gregory J Feldman.;Sanjay Sethi.;Selwyn Spangenthal.;Gregory M Gottschlich.;Roberto Rodriguez-Roisin.;Samir Arora.;Thomas M Siler.;Shahid Siddiqui.;Patrick Darken.;Tracy Fischer.;Andrea Maes.;Michael Golden.;Chad Orevillo.;Colin Reisner.
来源: Chest. 2017年151卷2期340-357页
Long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combinations are a treatment option for patients with COPD who continue to have symptoms despite treatment with a LAMA or a LABA alone. The Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate-to-Very Severe COPD (PINNACLE-1) (NCT01854645) and the Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate-to-Very Severe COPD (PINNACLE-2) (NCT01854658) trials investigated the efficacy and safety of a novel glycopyrrolate [GP]/formoterol [FF] 18/9.6-μg (GFF) metered dose inhaler (MDI) formulated using the Co-Suspension Delivery Technology in patients with moderate-to-very severe COPD.
|